arrow
A

Andreas Kuznik

Sanofi-Aventis
H指数:29
被引数:2,581

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Correction: Aflibercept 8 mg versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials

更正:Aflibercept 8 mg 与 Faricimab Treat-and-Extend 治疗糖尿病黄斑水肿或新生血管性年龄相关性黄斑变性:一项基于临床试验的贝叶斯固定效应网络meta分析

2026-04-040
OAAI
Aflibercept 8 mg versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials

Aflibercept 8 mg 与 Faricimab Treat-and-Extend 治疗糖尿病黄斑水肿或新生血管性年龄相关性黄斑变性:一项基于临床试验的贝叶斯固定效应网络Meta分析

2025-09-250
OAAI
Cost-Effectiveness of Cemiplimab Versus Standard of Care in the United States for First-Line Treatment of Advanced Non-small Cell Lung Cancer With Programmed Death-Ligand 1 Expression ≥50%

Cemiplimab与美国标准护理一线治疗程序性死亡配体1表达 ≥ 50% 的晚期非小细胞肺癌的成本效益

2022-02-0117
OAAI
Indirect Treatment Comparison of the Efficacy and Safety of Sarilumab Monotherapy in Rheumatoid Arthritis Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs

Sarilumab单药治疗对常规缓解疾病的抗风湿药物反应不足的类风湿关节炎患者的疗效和安全性的间接治疗比较

2019-03-128
OAAI